SCHEMBL5523684

SCHEMBL5523684

COc1ccc(Cl)cc1NC(=S)NCC1CCC(Nc2nc(N(C)C)c3ccccc3n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 11/20 0.51
MCHR1 Q99705 11/20 0.51
NPY5R Q15761 7/20 0.51
MAPT P10636 2/20 0.48
HTR1A P08908 1/20 0.45
ADRA1A P35348 1/20 0.45
HRH1 P35367 1/20 0.45
HTR2B P41595 1/20 0.45
LMNA P02545 1/20 0.45
ALPL P05186 1/20 0.45
ALPI P09923 1/20 0.45
ALPG P10696 1/20 0.45
ALOX12 P18054 1/20 0.45
HTT P42858 1/20 0.45
HPGD P15428 2/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030503 1.00 ADRA2A (0.51) ADRA2AMCHR1NPY5RMAPTHTR1A
SCHEMBL4531832 0.90 MCHR1 (0.53) ADRA2AMCHR1NPY5RMAPTHTR1A
SCHEMBL4531828 0.90 MCHR1 (0.53) ADRA2AMCHR1NPY5RMAPTHTR1A
SCHEMBL5518649 0.87 MCHR1 (0.54) ADRA2AMCHR1NPY5RMAPTHTR1A
SCHEMBL5518644 0.87 MCHR1 (0.54) ADRA2AMCHR1NPY5RMAPTHTR1A
SCHEMBL5522648 0.84 MCHR1 (0.53) ADRA2AMCHR1NPY5RHTR1AADRA1A
SCHEMBL5522652 0.84 MCHR1 (0.53) ADRA2AMCHR1NPY5RHTR1AADRA1A
SCHEMBL5522036 0.83 MCHR1 (0.53) ADRA2AMCHR1NPY5RMAPTHTR1A
SCHEMBL5522041 0.83 MCHR1 (0.53) ADRA2AMCHR1NPY5RMAPTHTR1A
SCHEMBL13796281 0.83 MCHR1 (0.63) ADRA2AMCHR1NPY5RHTR1AADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US claimed
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 ADRA2A 103/4885MCHR1 1/4885NPY5R 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.